Chronic graft vs. host disease and hypogammaglobulinemia predict a lower immunological response to the BNT162b2 mRNA COVID-19 vaccine after allogeneic hematopoietic stem cell transplantation

Barabino, L
;Galitzia, A;Caocci, G;Greco, M;Mulas, O;Costa, A;La Nasa, G
Last
2022-01-01

Abstract

Due to the high mortality rate of COVID-19, the assessment of BNT162b2 SARS-CoV-2 mRNA vaccine (Pfizer-BioNTech) efficacy in allogeneic hematopoietic stem cell transplant (HSCT) recipients is mandatory.
2022
BNT162b2; cGVHD; Chronic graft-versus-host-disease; COVID-19; Hypogammaglobulinemia; Transplantation; Vaccine
Files in This Item:
File Size Format  
8984-8989-1.pdf

open access

Type: versione post-print
Size 463.14 kB
Format Adobe PDF
View/Open
463.14 kB Adobe PDF View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Questionnaire and social

Share on:
Impostazioni cookie